ArticlemBio2016
Characterization of a Multipeptide Lantibiotic Locus in Streptococcus pneumoniae.
Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- RggmBio · 2026Article
- Article
- Increasing prevalence of bacteriocin carriage in a 6-year hospital cohort ofJournal of bacteriology · 2024Article
- Increasing prevalence of bacteriocin carriage in a six-year hospital cohort ofmedRxiv : the preprint server for health sciences · 2024Article
- Nasopharyngeal competition dynamics are likely to be altered following vaccine introduction: bacteriocin prevalence and diversity among Icelandic and Kenyan pneumococci.Microbial genomics · 2023Article
- Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Epidemiological dynamics of bacteriocin competition and antibiotic resistance.Proceedings. Biological sciences · 2022Article
- Gene Expression Regulation in Airway Pathogens: Importance for Otitis Media.Frontiers in cellular and infection microbiology · 2022Review
- Intra-Species Interactions inFrontiers in cellular and infection microbiology · 2021Article
- The pneumococcal social network.PLoS pathogens · 2020Review
- Proteomic Characterization of Antibiotic Resistance, and Production of Antimicrobial and Virulence Factors inAntibiotics (Basel, Switzerland) · 2020Article
- Genetic Analysis of Mutacin B-Ny266, a Lantibiotic Active against Caries Pathogens.Journal of bacteriology · 2020Article
- Impact of microbiome-based interventions on gastrointestinal pathogen colonization in the intensive care unit.Therapeutic advances in gastroenterology · 2020Review
- Complete Genome Sequence of Megaplasmid-Bearing Streptococcus salivarius Strain LAB813, Isolated from the Dental Plaque of a Caries-Free Child.Microbiology resource announcements · 2019Article
- Profiling microorganisms in whole saliva of children with and without dental caries.Clinical and experimental dental research · 2019Article
- Characterization of the Competitive Pneumocin Peptides ofFrontiers in cellular and infection microbiology · 2019Article
- CerR, a Single-Domain Regulatory Protein of the LuxR Family, Promotes Cerecidin Production and Immunity in Bacillus cereus.Applied and environmental microbiology · 2018Article
- Genome Sequencing Reveals a Large and Diverse Repertoire of Antimicrobial Peptides.Frontiers in microbiology · 2018Article
- Article
- Frequency-dependent selection in vaccine-associated pneumococcal population dynamics.Nature ecology & evolution · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledBacterial communities are established through a combination of cooperative and antagonistic interactions between the inhabitants. Competitive interactions often involve the production of antimicrobial substances, including bacteriocins, which are small antimicrobial peptides that target other community members. Despite the nearly ubiquitous presence of bacteriocin-encoding loci, inhibitory activity has been attributed to only a small fraction of gene clusters. In this study, we characterized a novel locus (the pld locus) in the pathogen Streptococcus pneumoniae that drives the production of a bacteriocin called pneumolancidin, which has broad antimicrobial activity. The locus encodes an unusual tandem array of four inhibitory peptides, three of which are absolutely required for antibacterial activity. The three peptide sequences are similar but appear to play distinct roles in regulation and inhibition. A modification enzyme typically found in loci encoding a class of highly modified bacteriocins called lantibiotics was required for inhibitory activity. The production of pneumolancidin is controlled by a two-component regulatory system that is activated by the accumulation of modified peptides. The locus is located on a mobile element that has been found in many pneumococcal lineages, although not all elements carry the pld genes. Intriguingly, a minimal region containing only the genes required for pneumolancidin immunity was found in several Streptococcus mitis strains. The pneumolancidin-producing strain can inhibit nearly all pneumococci tested to date and provided a competitive advantage in vivo. These peptides not only represent a unique strategy for bacterial competition but also are an important resource to guide the development of new antimicrobials. IMPORTANCE: Successful colonization of a polymicrobial host surface is a prerequisite for the subsequent development of disease for many bacterial pathogens. Bacterial factors that directly inhibit the growth of neighbors may provide an advantage during colonization if the inhibition of competitors outweighs the energy for production. In this work, we found that production of a potent antimicrobial called pneumolancidin conferred a competitive advantage to the pathogen Streptococcus pneumoniae. S. pneumoniae secreting pneumolancidin inhibits a wide array of Gram-positive organisms, including all but one tested pneumococcal strain. The pneumolancidin genetic locus is of particular interest because it encodes three similar modified peptides (lantibiotics), each of which has a distinct role in the function of the locus. Lantibiotics represent a relatively untapped resource for the development of clinically useful antibiotics which are desperately needed. The broad inhibitory activity of pneumolancidin makes it an ideal candidate for further characterization and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.